To the Editor:
A recently published article ''Contaminated heparin associated with adverse clinical events and activation of the contact system, '' Kishimoto et al, New England Journal of Medicine, 2008; 358:2457 -2467 discussed the role of oversulfated chondroitin sulfate (OSCS) in contaminated heparin in reference to adverse clinical events and the activation of the contact system. The authors concluded that this article provided is scientific rationale for the potential biologic link between OSCS and observed clinical events. Moreover, the authors suggested that a simple nonspecific amidolytic method for the generation of kallikrein could be used for the screening of OSCS and other highly sulfated polysaccharide components in heparin. This article implied that contact activation leading to the generation of kallikrein and subsequent formation of bradykinin is responsible for the anaphylactic responses in patients anticoagulated with heparin.
The authors are to be commended for the expeditious work of the preliminary experiments to address their hypothesis which, OSCS is primarily responsible for the reported adverse events after the administration of contaminated heparin. However, most of the interpretations are based on speculation and the reported data are grossly overinterpreted. The reported adverse reactions and death with the use of contaminated heparin represents complex pathophysiologic responses with multifactorial etiologies where OSCS mediated contact activation, may or may not have played a role.
Although OSCS represents one of the main detectable contaminants, the recalled heparin preparations may also contain several other heparin-like and nonheparin substances, which have not been fully investigated, and their association with the reported adverse events is not established at this time. The contaminated heparins also contained highmolecular-weight dermatan sulfate which itself may have complex interactions with heparin and OSCS.
The single-case reports described by the authors on the patient developing hypotension and other adverse reactions during dialysis represents an incidental finding and the authors fail to describe the nature of anaphylactoid reaction. Moreover, none of the plasma markers and other workups for anaphylaxis was reported. In addition, the authors did not provide the amount of contaminant in the heparin preparation that this patient was exposed. This single-case report does not prove cause/effect for OSCS in producing anaphylaxis.
In a recent news article in the Chicago Tribune, Wednesday, July 30, 2008/Section 3, the Food and Drug Administration (FDA) said ''it completed its review of 93 deaths reports related to heparin that the agency reviewed from Jan. 1st to March 31st, when reports of heparin adverse reactions peaked.'' Of the 10 cases of severe anaphylaxis and hypotension, only 3 of those were reported traced to the lot numbers of heparins that tested positive for OSCS. The cause for the other 7 deaths was not determined. Of the remaining 83 reports, the cause of deaths was complex and included bleeding. The details of the 3 reported deaths, which were linked to OSCS containing heparin, were not available. It is important that supportive data on the levels of contact mediated activation products such as bradykinin, anaphylotoxins, and other mediators should be provided to prove cause and effect. Interestingly, even after the reported recall of contaminated heparin earlier this year, the number of reported deaths and the reported deaths with one or more allergic/hypotensive symptoms remained significantly high (March 2008) . Because of the recall of the contaminated heparin, one would have expected a proportionate decrease during this period. Therefore, the recent assertions that 3 deaths associated with contaminated heparins provide proof for definitive cause and effect maybe premature.
The reported amidolytic activity of generated kallikrein represents a nonspecific method and which should have been evaluated in conjunction with prekallikrein and high-molecular-weight kininogen levels in various systems studied. Moreover, the amount of kallikrein generated varied widely and the relevance to bradykinin was not established. Heparin itself is capable of activating contact system and the extent of this activation largely varies in both the normal individuals and patients. Other heparin-related agents are also capable of causing activation of contact system. Not to mention the complex contribution of antihypertensive drugs and extracorporeal devices.
The reported in vivo studies using a pig model represent only a few animals per group with wide variations. For example, of the 6 pigs treated with OSCScontaminated heparin, only 2 showed a clear drop in blood pressure. It is not surprising that of the 3 pigs treated with OSCS, a profound drop on blood pressure was observed. This material has never been tested for these observed effects, which may be related to several additional factors such as the molecular weight, degree of sulfation, and the release of other mediators such as nitric oxide. The authors should have provided supportive evidence of the generation of hypotensive mediators in conjunction with prekallikrein and high-molecular-weight kininogen. Moreover, the generation of kallikrein in the pig treated with contaminated heparin and OSCS does not correspond with the observed hypotensive effects in these studies. Furthermore, the concentration of heparin and related agents was rather high in these studies.
From a statistical standpoint, the interpretations on the relevance of contact activation mediated generation of bradykinin in the in vitro studies and pig model may not be relevant to the adverse reactions and deaths. The behavior of OSCS when injected in combination with heparin may be different when compared with OSCS administered alone. The authors have stated that 5 mg/kg of OSCS-contaminated heparin was given to 6 pigs in a single intravenous dose. The amount of OSCS in this preparation should have been defined. Moreover, a dose-dependent effect of OSCS was not discussed to justify the anaphylactoid response.
Although the pathogenesis of OSCS-contaminated heparins is primarily linked with contact activation and the authors have totally ignored other pathophysiologic mechanisms, such as the generation of antibodies in patients who have been repeatedly exposed to these products, oversulfated glycosaminoglycans (GAGs) bind much strongly to heparin-binding proteins such as platelet factor 4 and related polycationic proteins. Moreover, OSCS may interact with various endothelial, blood cellular and plasmatic proteins. It should be stressed that repeated exposure of OSCS-containing heparin could easily lead to the generation of a wide array of antibodies, which may mediate complex pathophysiologic responses. Moreover, such responses maybe population dependent resulting in variable pathophysiologic effects. To date, neither the article by Kishimoto et al nor the regulatory statement from different agencies have considered the immunogenic implications and their relevance to the pathogenesis of anaphylactic responses in those patients who suffered severe reactions. It is important to take into consideration the immunogenic effects of OSCS and other contaminants while investigating a cause and effect of the reported death. Simply pointing to the activation of contact system activation as the sole cause for these complex events in those patients who suffered from these catastrophic adverse effects is not acceptable at this time.
The authors also failed to discuss the effect of OSCS on blood coagulation and platelet count in the animals treated with this agent. Moreover, the interaction with OSCS with heparin in terms of anticoagulant responses is not discussed. Oversulfated chondroitin sulfate may potentially exhibit several pharmacodynamic interactions with heparin. Such interactions are equally important to explain the pathogenesis related to the use of contaminated heparin. The recalled heparin preparations also contained dermatan sulfate. Therefore, complex interactions between dermatan sulfate, OSCS, and heparin are to be expected. Both the OSCS and dermatan sulfate produced anticoagulant effects and exhibits varying degrees of interactions with this anticoagulant. Therefore, it is not surprising that some of the patients treated with contaminated heparin also exhibited bleeding complications.
In conclusion, the nature of the reported adverse events related to the use of contaminated heparin is complex and multifactorial, which is further compounded by patient's predispositions. Although this article by Kishimoto et al provides preliminary data on the generation of kallikrein and anaphylotoxins by OSCS, these results are at best preliminary and should not be considered for a cause/effect for the catastrophic hypotensive syndrome leading to death in more than 100 patients. Therefore, until further observations in well-designed and statistically valid studies, this preliminary report should be considered with extreme caution. It should also be stressed that the effect of contaminants, in particular OSCS on hemostatic systems, in particular blood coagulation and platelet activation with the immunogenic potential with reference to the generation of antibodies represents additional potential pathogenic mechanisms which may contribute to the observed adverse events and deaths.
